|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
Re: Diflucan and OCsFrom: Terrence.Jones@kp.orgThu Nov 13 16:49:54 2003
This is a multipart message in MIME format. --=_alternative 0076616D88256DDD_ Content-Type: text/plain; charset="us-ascii" Ron, inhibition of P-450 mediated sterol synthesis in cell membrane of Candida (Azoles) should, if anything, enhance the efficacy of OC's (Davenport, Br J Pharm, 6/89 27:851-9). The Pfizer study demonstrated this (O/G 8/01, 98:218-23), and is supported by Robert Wood Johnson study (Am J O/G 2/98, 178:300-4). Both of these, as You mentioned, were short term dose investigations, using Patients as their own controls. What data did the monograph refer to? tj ainsron@sbcglobal.net (Dr. Ainsworth) Sent by: ob-gyn-l@obgyn.net 11/13/2003 11:10 AM Please respond to ob-gyn-l To: Multiple recipients of list OB-GYN-L <ob-gyn-l@dns.obgyn.net> cc: Subject: Diflucan and OCs A pharmacist recently sent me a note to find out if I "really wanted to prescribe Diflucan, 150mg" for a uncomplicated yeast infection on a patient on OCs. He sent me a drug interaction monograph that reported several pregnancies in patients on OCs. On reviewing it, all of the patients they discussed were on long-term Diflucan, not a single daily dose. Do any of you have concerns about Diflucan and OCs? I don't. --=_alternative 0076616D88256DDD_ Content-Type: text/html; charset="us-ascii" <br><font size=2 face="sans-serif">Ron, inhibition of P-450 mediated sterol synthesis in cell membrane of Candida (Azoles) should, if anything, enhance the efficacy of OC's (Davenport, Br J Pharm, 6/89 27:851-9). The Pfizer study demonstrated this (O/G 8/01, 98:218-23), and is supported by Robert Wood Johnson study (Am J O/G 2/98, 178:300-4). Both of these, as You mentioned, were short term dose investigations, using Patients as their own controls. What data did the monograph refer to? tj</font> <br> <table width0%> <tr valign=top> <td> <td><font size=1 face="sans-serif"><b>ainsron@sbcglobal.net (Dr. Ainsworth)</b></font> <br><font size=1 face="sans-serif">Sent by: ob-gyn-l@obgyn.net</font> <p><font size=1 face="sans-serif">11/13/2003 11:10 AM</font> <br><font size=1 face="sans-serif">Please respond to ob-gyn-l</font> <br> <td><font size=1 face="Arial"> </font> <br><font size=1 face="sans-serif"> To: Multiple recipients of list OB-GYN-L <ob-gyn-l@dns.obgyn.net></font> <br><font size=1 face="sans-serif"> cc: </font> <br><font size=1 face="sans-serif"> Subject: Diflucan and OCs</font></table> <br> <br><font size=2 face="Courier New">A pharmacist recently sent me a note to find out if I "really wanted to<br> prescribe Diflucan, 150mg" for a uncomplicated yeast infection on a<br> patient on OCs. He sent me a drug interaction monograph that reported<br> several pregnancies in patients on OCs. On reviewing it, all of the<br> patients they discussed were on long-term Diflucan, not a single daily<br> dose. Do any of you have concerns about Diflucan and OCs? I don't.<br> <br> </font> <br>
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Jul 2 04:36:19 2008 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.